

A colostrum-based bladder instillation relieved BPS pain as much as hyaluronic acid

VAS pain reduction: -37.9% vs -37.8%

97% of the comparator effect (non-inferiority threshold: 80%)

Fanara F¹, Abbate N¹, Grasso A¹, Feliciangeli V¹, Mollo L¹, Cusumano C¹, Martin G¹, Pletto S¹, Rosato E¹, Finazzi Agrò E¹


¹ University of Rome Tor Vergata

Evaluation of a New Intravesical Compound Containing Purified Colostrum and Chondroitin Sulfate in the Management of Bladder Pain Syndrome: A Pilot Non-Inferiority Study

BACKGROUND & AIM

GAG-layer replenishment is a recommended option for BPS in the EAU Guidelines. We compared a new instillation of purified colostrum + chondroitin sulfate (Controcyst®) with the standard hyaluronic acid + chondroitin sulfate (Ialuril Prefill®).

METHODS




Outcomes: VAS pain, IPSS, IPSS-QoL at baseline and end of treatment; PGI-I at end of treatment.

Non-inferiority: VAS reduction in Group A $\geq$ 80% of the reduction in Group B.

RESULTS

All 40 patients (age 33–76) completed the study



	Controcyst®	Ialuril Prefill®
IPSS	18.25 → 14.00	19.10 → 16.05
IPSS-QoL	3.80 → 2.55	4.80 → 3.15
PGI-I (mean)	2.35	2.85

All within-group changes significant ($p \leq 0.045$). Improvements stable at 3 and 6 months. Lower PGI-I = greater perceived improvement.

CONCLUSION

In this pilot study, Controcyst® met the pre-specified non-inferiority criterion versus Ialuril Prefill® on pain, with comparable gains in symptoms and quality of life. Larger multicentre RCTs are needed to confirm these preliminary data.